Modernizing Pharma Manufacturing through Technology & Innovation
The 2017 ISPE/FDA/PQRI Quality Manufacturing Conference offers a new and exciting format where participants will be able to interact directly with pharmaceutical industry and regulatory leaders in a four-series workshop rotation. Today’s blog focuses on the details of Modernizing Pharmaceutical Manufacturing through Emerging Technology and Innovation, one of four core workshops taking place at the conference.
New and even existing products often benefit from the implementation of new commercial manufacturing technologies. With the FDA’s new guidance on emerging technologies, the pharmaceutical industry is embracing the opportunity to bring new technologies to life to support robust manufacturing of products. However, the pharmaceutical industry is a global business and manufacturing technologies of this type must be globally accepted.
Objective of the Workshop:
- Share concerns and perspectives on the implementation of new technologies
- Explore how control strategies might be similar and/or different between traditional and new technologies
- Learn and share industry success stories and identify possible new opportunities and best practices
- Gabriella Dahlgren, PhD, Manager, Analytical Sciences & Technology, Advanced Analytics and Design to Value, Janssen Supply Group
- John Lepore, PhD, Senior Director Chemical Engineering, Merck & Co., Inc.
- Frank Montgomery, PhD, Global Head, Regulatory CMC, AstraZeneca
- Mohan Sapru, PhD, Quality Assessment Lead (Acting), Office of New Drug Products, and Emerging Technology Team Member, FDA/CDER/OPQ
Tired of listening to talk after talk? Learn why the 2017 IPSE/FDA/PQRI Quality Manufacturing Conference will be unlike any pharmaceutical industry conference you’ve experienced before!
2017 ISPE/FDA/PQRI Quality Manufacturing Conference
The 5th Annual ISPE/FDA/PQRI Quality Manufacturing Conference offers you the unique opportunity to interact directly with industry and regulatory leaders to identify real solutions to your organization’s challenges on key issues. Sessions are designed to encourage open discussion about current FDA priorities and industry-critical quality initiatives.